On September 26, 2018 Kitov Pharma (NASDAQ/TASE: KTOV), an innovative biopharmaceutical company, reported that Hadas Reuveni, Ph.D., Chief Technology Officer at Kitov’s subsidiary, TyrNovo Ltd., will present pre-clinical data on NT219, an anti-tumor resistance drug candidate, in a poster session at the Fourth CRI-CIMT-EATI-AACR International Cancer Immunotherapy Conference (CIMT) (Free CIMT Whitepaper): Translating Science into Survival, to be held September 30 – October 3, 2018, in New York (Press release, Kitov Pharmaceuticals , SEP 26, 2018, View Source [SID1234529701]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"We are pleased to have been chosen to present an abstract at the upcoming AACR (Free AACR Whitepaper) meeting. These very exciting data, which we had also presented at a cancer conference earlier this year, hold great promise for mobilizing the patient’s immune system against tumors," Dr. Reuveni commented. "In the future, tumors in patients who have functional immune systems may respond to NT219 both by blocking feedback pathways, overcoming drug resistance, and by removing the ‘protective shield’ from the tumor, allowing anti-tumor immune attack."

The poster demonstrates NT219’s efficacy in synergy with immuno-oncology therapies, which are widely used today, but to which unfortunately most patients still do not respond. In double autologous PDX models, dosing with NT219 converted tumors that were resistant to pembrolizumab (Keytruda) into responsive tumors. The models also demonstrated the efficacy of NT219 in enhancing the immunotherapeutic potential of cetuximab (Erbitux).

Abstract: B127
Abstract Title: NT219, A Novel Dual Inhibitor of STAT3 and IRS1/2, Converts Immuno-Oncology Resistant Tumors to Responders
Session Date: Tuesday, October 2, 2018
Session Time: 12.45 p.m. – 3.15 p.m. EDT
Session Location: Poster Session B, New York Marriott Marquis, Westside Ballroom

About NT219

NT219 is a small molecule that presents a new concept in cancer therapy by promoting the degradation and inhibiting the phosphorylation of two oncology-related checkpoints, Insulin Receptor Substrates (IRS) 1/2 and signal transducer and activator of transcription 3 (STAT3), respectively. While targeted anti-cancer drugs inhibit the "ON" signal, NT219 activates the "OFF" switch, extensively blocking major oncogenic pathways. In pre-clinical trials, NT219, in combination with several approved cancer drugs, displayed potent anti-tumor effects and increased survival in various cancers, including sarcoma, melanoma, pancreatic, lung, head & neck, prostate and colon cancers, by preventing the tumors from developing drug resistance and reversing resistance after it had been acquired. NT219 is developed by TyrNovo Ltd., a Kitov Pharma company. For more information on TyrNovo please visit View Source